Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

910
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
910
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.9K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.9K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.6K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From monoclonal to polyfunctional immunotherapy: Reprogramming CAR-T-cell therapy with oncolytic viruses in B-cell malignancies.

HemaSphere·2026
Same author

Silibinin-Loaded Proniosomal Gel for Cutaneous Application: Pharmaco-Technical Characterization and In Vitro-In Ovo Biocompatibility.

Gels (Basel, Switzerland)·2026
Same author

Therapy-Induced Cellular Senescence in Non-Hodgkin Lymphomas, with Emphasis on Aggressive B-Cell Subtypes: Molecular Mechanisms and Emerging Drug Targets.

Current cancer drug targets·2026
Same author

Case Report: Successful concomitant surgical interventions for dilated ascending aorta and aortic valve insufficiency in a severe haemophilia A case.

Frontiers in medicine·2026
Same author

Integrating Flow Cytometry in the Diagnostic Work of HIV-Associated Hodgkin's Lymphomas.

Journal of cellular and molecular medicine·2026
Same author

The crosstalk between epigenetics and metabolism in the malignant cell.

Discover oncology·2026

Related Experiment Video

Updated: Jan 18, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.0K

Adoptive cellular therapies in multiple myeloma.

David Kegyes1, Bogdan Borlea1, Marc Damian2

  • 1Department of Personalized Medicine and Rare Diseases, Medfuture Institute for Biomedical Research - Department of Hematology, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.

Best Practice & Research. Clinical Haematology
|September 7, 2025
PubMed
Summary

Chimeric antigen receptor (CAR) T-cell and NK-cell therapies show promise for treating plasma cell myeloma. These advanced immunotherapies are increasingly effective, even in earlier treatment stages and as alternatives to stem cell transplantation.

Keywords:
CAR NK-CellsCAR T-cellsChimeric antigen receptorImmunotherapyMultiple myeloma

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.5K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.9K

Related Experiment Videos

Last Updated: Jan 18, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.0K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.5K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.9K

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Plasma cell myeloma, a bone marrow cancer, involves abnormal plasma cell growth.
  • Treatment options are continuously advancing with new drug approvals.
  • Chimeric antigen receptor (CAR) therapies represent a significant advancement in immunotherapy.

Purpose of the Study:

  • To review the history and recent progress of CAR T-cell and NK-cell therapies for plasma cell myeloma.
  • To highlight the evolving role of CAR therapies in myeloma treatment paradigms.

Main Methods:

  • Literature review of CAR T-cell and NK-cell therapy advancements.
  • Analysis of current research on early-stage and relapsed/refractory plasma cell myeloma treatment.

Main Results:

  • CAR therapies have demonstrated success in relapsed or refractory multiple myeloma.
  • Evidence suggests CAR therapies are effective in earlier treatment lines, potentially replacing autologous stem cell transplantation.
  • Ongoing research focuses on expanding CAR therapy to solid tumors and improving safety and efficacy.

Conclusions:

  • CAR T-cell and NK-cell therapies are rapidly evolving and highly effective treatments for plasma cell myeloma.
  • These immunotherapies offer new hope and alternative strategies for patients with multiple myeloma.